Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03486301 · ClinicalTrials.gov registry record · Phase 1
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab
A Phase 1 study, sponsored by Eikon Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
NCT03486301 is a Phase 1 study that has completed, run by Eikon Therapeutics. The registered enrollment target is 87 participants.
The verdict
NCT03486301, a Phase 1 study, has completed, sponsored by Eikon Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Interventions
- DRUG Pembrolizumab
- DRUG BDB001 (EIK1001)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2018-02-15 |
| Est. Completion | 2024-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03486301
The ClinicalTrials.gov registry entry for NCT03486301 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eikon Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03486301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03486301 about?
NCT03486301 is a clinical study titled "BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab". Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors
What is the current status of trial NCT03486301?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2018-02-15. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT03486301?
The interventions under investigation include: Pembrolizumab (DRUG), BDB001 (EIK1001) (DRUG).
Who is sponsoring clinical trial NCT03486301?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.